Publications Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies September 27, 2019 Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR. ESMO Annual Congress. . https://www.annalsofoncology.org/article/S0923-7534(19)59501-1/pdf Authors:Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR Sources:ESMO Annual Congress Read the research SharePosted inComparative effectivenessSkin cancer More publicationsOctober 2026Real-world comparative effectiveness of trifluridine-tipiracil + bevacizumab vs trifluridine-tipiracil in patients with refractory metastatic colorectal cancer in the United StatesMay 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancerMay 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab
October 2026Real-world comparative effectiveness of trifluridine-tipiracil + bevacizumab vs trifluridine-tipiracil in patients with refractory metastatic colorectal cancer in the United States
May 2026Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first- line induction and maintenance regimens in extensive-stage small cell lung cancer
May 2026Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab